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ORIGINAL RESEARCH
Abstract: In Australia, physiotherapy is a primary contact profession when practiced in private
ambulatory settings. Primary contact means that physiotherapists take responsibility for
diagnosis, decisions on interventions, appropriate ongoing management, and costs related to
benefits. For most physiotherapists, the most common clinical presentations relate to symptoms
from musculoskeletal conditions. There is considerable research evidence for many
“physiotherapy” techniques in the management of musculoskeletal symptoms. As part of these
management strategies, some physiotherapists may use nonsteroidal antiinflammatory drugs
(NSAIDs) as an adjunct to treatment. Physiotherapists do not have the training or the legislative
powers to prescribe NSAIDs. However, they can recommend that patients seek advice about
appropriate adjunct NSAIDs from pharmacists and/or medical practitioners. The roles and
responsibilities of key health providers in this area appear to be well defined in terms of
minimizing medication misadventure and optimizing patient health outcomes. A recent survey
of physiotherapist behaviors and practices, however, identified a number of “gray” areas that
could confront unwary physiotherapists, or pose dilemmas for those without the support of
medical/pharmacist colleagues. These gray areas relate to the adjunct use of topical NSAIDs
in physiotherapy management and making recommendations for the use of oral NSAIDs.
This paper reports on qualitative data that highlights the dilemmas confronting physiotherapists.
Keywords: physiotherapy, antiinflammatory agents, legal and ethical issues
Introduction
Physiotherapists in Australia often work in community settings as primary contact
practitioners where they treat a range of musculoskeletal conditions, from acute sprains
and strains to chronic inflammatory conditions (Grimmer et al 1998). As highlighted
by Moore et al (1998), nonsteroidal antiinflammatory drugs (NSAIDs) are by far the
most common pharmaceuticals used for managing these symptoms and, hence, are
often adjunct therapy to physiotherapy management of musculoskeletal conditions.
The cost to the Australian community in the management of musculoskeletal disorders
is in excess of 15 billon Australian dollars per annum (Access Economics 2001a,
2001b cited in AAMPGG 2003), and given the recent recognition of the role of
physiotherapy in the management of chronic musculoskeletal conditions by the
Australian Government Medicare legislation (Commonwealth Department of Health
and Ageing 2003), it could be presumed that the place of physiotherapy in managing
musculoskeletal conditions is assured in the eyes of the public. In recent years, there
has been improved community access to NSAIDs. Due to changes to drug scheduling,
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many common NSAIDs are now available in non-
prescription over-the-counter forms in supermarkets and
pharmacies.
The assumption underlying the purchase of NSAIDs
from a pharmacy is that appropriate professional advice
would be supplied along with the drug at the point of sale.
This information is currently not available in the
supermarket. More potent NSAIDs are available on
prescription from medical practitioners.
The Quality Use of Medicines policy refers to selecting
appropriate pharmaceutical management, and advising on
the safe and effective use of medicines (Commonwealth
Department of Health and Ageing 2002). Current legislation
in Australia precludes physiotherapists from prescribing,
supplying, or selling NSAIDs in their clinical settings. The
scheduling of therapeutic drugs is monitored via the
Standard for the Uniform Scheduling of Drugs and Poisons,
which is adopted from the South Australia Controlled
Substances (Poisons) Regulation, 1996. The legislation
governing access to scheduled medicines is the Controlled
Substances Act 1984 and the Controlled Substances
(Poisons) Regulation 1996. As per these legislations, only
medical practitioners and dentists are permitted to prescribe
Schedule 4 (prescription-only) medicines within the
ordinary course of their profession. Access to these
medicines would be through the dispensing of such a
prescription by a pharmacist. Access to Schedule 2 pharmacy
and Schedule 3 pharmacist-only medicines is also only from
a pharmacy. Physiotherapists are not permitted to prescribe,
sell, or supply Schedule 2, 3, and 4 medicines.
The gray area related to physiotherapist involvement
with NSAIDs concerns the reference to drugs that are
classified as S2 Expect; ie, the product is unscheduled and
therefore can be sold outside pharmacies such as in
supermarkets. While the legislation is very clear on the
supply, sale, and use of S2, 3, and 4, the legislation does not
control the sale or supply of unscheduled medicines. This
has been left as a matter of professional practice.
This legislation  protects physiotherapists from situations
where their limited training in pharmacology could
inadvertently place their patient at risk of greater harm than
good when using NSAIDs as an adjunct to physiotherapy
management. Thus, the expected approach taken by
physiotherapists to ensure that patients use NSAIDs
appropriately as an adjunct to physiotherapy management
is for the physiotherapist to recognize the potential role of
oral or topical NSAIDs in individual symptom management,
then to recommend this in a general sense to the patient,
and to advise the patient to discuss the matter further with
the pharmacist or the general medical practitioner. It is
inappropriate for physiotherapists to recommend a particular
brand of NSAIDs to a patient (which is seen as anecdotal
evidence) or to provide NSAIDs (stock or sell) in any form
in the physiotherapy clinic. Grimmer et al (2002), reporting
on quantitative data from a survey of physiotherapists,
highlighted legal and ethical issues underpinning the use of
NSAIDs in every day clinical practice. These findings were
supported by Lansbury and Sullivan (1998, 1999) who also
identified the need for educating physiotherapists on aspects
of NSAIDs.
It seems clear that there is the potential for patients who
have experienced a NSAIDs misadventure as a result of
inappropriate recommendation by a physiotherapist (without
seeking advice from appropriate health professionals), to
undertake legal action against the physiotherapist.
Typical symptoms of medication misadventure from
NSAIDs are listed in Table 1. Drugs with which NSAIDs
ingestion is currently considered inappropriate are listed in
Table 2.
Table 1 Commonly reported side effects with NSAIDs
Systems affected Symptoms reported
Gastrointestinal Heartburn, dyspepsia, diarrhea, constipation,
abdominal pain, nausea, stomatitis,
decreased appetite, vomiting
Central nervous system Headache, insomnia, dizziness, drowsiness,
tinnitus, confusion (more common in the
elderly), unusual weakness 
Ocular Visual disturbances such as loss of visual
acuity, blurred, or double vision
Dermatologic Itching, skin rash, photosensitivity reactions,
eruptions, hives
Cardiovascular Edema, palpitations, fast heartbeat
Genitourinary Dysuria, vaginal bleeding, blood in urine,
cystitis
Source: Data adapted from Lukazewski (2004).
Abbreviation: NSAIDs, nonsteroidal antiinflammatory drugs.
Table 2 Types of drugs contraindicated/interactions with
NSAIDs
Anticoagulants
ASPRIN/DISPRIN
Antihypertensives
Asthma medications
Lithium
Some cardiac medications
Source: Data adapted from AMA-CME (2004).Therapeutics and Clinical Risk Management 2005:1(1) 71
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This paper reports qualitative evidence on the
understanding of the role of physiotherapists in the use,
recommendation, and delivery of NSAIDS. The 2002 survey
involved interviews with physiotherapists working in a range
of practice settings in Australia. Providing additional and
adjunct findings to those reported in Grimmer et al (2002),
this paper summarizes qualitative findings of the same
study. Pitfalls for physiotherapists regarding inappropriate
NSAIDs practices are highlighted, and the need for
physiotherapists to be regularly informed of legislative
requirements is discussed.
Methods
Ethical approval
Ethical approval was provided by the University of South
Australia, and participants provided verbal consent to
participate in the project.
Subjects
The subjects were a purposive sample of physiotherapists
registered to practice in South Australia (SA), Tasmania,
and the Australian Capital Territory (ACT). These three sites
provided ideal comparisons for collecting information on
physiotherapists’ knowledge, behaviors, and attitudes to
NSAIDs because they reflected different types of practice
locations, as well as the influence of teaching schools and
professional practice philosophies. Physiotherapists in ACT
reflected generally urban or semi-rural practice, whilst
physiotherapists in SA and Tasmania were a mix of urban,
large, and small rural and remote practices. At the time of
the survey (2001–2002), there were no physiotherapy
university teaching schools in Tasmania or ACT.
Purposive sampling was the sampling method of choice
as dictated by the research design of the project (Barbour
2001). These physiotherapists were identified by members
of the project steering committee, as those who were
interested in medication usage in physiotherapy practice.
Attempts were made to ensure the subjects were evenly
distributed throughout the three states and were a diverse
group representing both private and public practitioners. The
steering committee consisted of different stakeholders from
the physiotherapy profession and external agencies (three
experienced private practitioners from the three participating
states, two experienced public practitioners). This included
the head of a physiotherapy school, the director of the local
branch of the Australian Physiotherapy Association, a health
economist, and a surveyor of a quality endorsement program
of the Australian Physiotherapy Association. These members
were asked to identify key private and public practitioners
within their respective states for individuals who had an
interest in medications and its use in physiotherapy.
Data collection and analysis
In-depth telephone interviews were conducted with
consenting physiotherapists to establish a framework of
knowledge and use of NSAIDs in clinical practice, and to
identify issues of concern regarding physiotherapists and
NSAID use. These interviews were conducted over a period
of one month and typically each interview was conducted
for approximately 20 minutes. Interviews were conducted
by one of the research team (SK) based on a series of
questions outlined in a semi-structured format. The questions
were provided to physiotherapists prior to the interview.
The interviews were audio taped, later transcribed, and
synthesized by key themes and concepts. These synthesized
findings were validated using hand written notes taken
during the interviews to verify the trustworthiness and
credibility of the data. Data were collected from participants
until saturation was attained (Rice and Ezzy 1999). Follow-
up interviews were conducted if additional information
and/or clarification of the initial interview data were required.
Results
Subject demographics
Forty-two physiotherapists were identified by the project
steering committee as key practitioners with an interest in
NSAIDs and their use in physiotherapy. One of the research
team (SK) invited these physiotherapists by phone or email
to participate in the project. Twelve physiotherapists either
rejected the invitation due to various reasons or were unable
to be contacted. Common reasons for not participating in
the study were lack of time, heavy current work load,
holidays, or illness. Thirty physiotherapists provided consent
to participate, and were interviewed for this study (17 men
and 13 women). The average age (standard deviation) was
not significantly different for men and women, being 38.8
(SD 9.8) years for men and 40.4 (SD 7.8) years for women.
Fourteen of the participants were from SA, eight from ACT,
and eight from Tasmania. These proportions reflected the
proportions of physiotherapists registered to work in these
states at this time (personal communication with
Physiotherapy Registration Boards in each of theseTherapeutics and Clinical Risk Management 2005:1(1) 72
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states 2002). There were different percentages of male and
female participants working in public and private sectors
(Figure 1); however, there was no significant influence of
location (state) on these percentages.
Follow-up interviews were conducted with only three
physiotherapists to clarify issues that were raised during
the initial interviews. The remainder of the interviews
provided complete data and required no further exploration.
Key themes
Key themes synthesized from the interviews are outlined in
Table 3. The following sections provide details on each of
the key themes raised by the participants. Excerpts taken
from the interviews are included.
Common questions asked of
physiotherapists
All participants reported that patients regularly asked a range
of questions about the nature, use, indications and
contraindications, and interactions of NSAIDs. Almost all
the interviewed physiotherapists agreed that patients were
not fully informed or knowledgeable about these
medications and that they perceived physiotherapists as
having reliable and up-to-date knowledge in this area. (See
following excerpt.)
I don’t believe that physiotherapists should take a role in
drug therapy advice – just as I don’t believe we should
give advice on diet. General advice is OK, but always
back it up with suggestions that they speak to their
GP/pharmacist.
I feel I don’t have the knowledge or expertise to
recommend NSAIDs, especially to an aged population who
are more likely to have conditions which are
contraindicated for NSAIDs. GPs and pharmacists have
knowledge of drug adverse reactions as well as medication
interactions. Patients don’t always know the details of their
current medications or medical history and so
physiotherapists shouldn’t be responsible for NSAID
prescription or advice.
Commonly encountered NSAID oral
medications and topical gels
Respondents reported that there were a number of NSAID
oral medications and topical gels that they commonly
encountered – either from patient discussions, or through
personal experience. Physiotherapists reported that they
were often put in situations where they had to “recommend”
these medications to patients. With respect to topical agents,
there were differing opinions by physiotherapists about
NSAIDs efficacy, and few physiotherapists were aware of
up-to-date research information (such as systematic reviews)
that provided best practice information. An area of real
concern was in therapists’ knowledge about topical NSAIDs
(ie, their efficacy as an adjunct to physiotherapy
management, whether there was a systemic effect on the
patient, or whether there were any potentially adverse effects
for the therapist administering it).
Physiotherapists are in an ideal position to reinforce
the advice of GPs re NSAIDs – both their indications
and precautions. Physios are often the first contact
practitioner and need to know enough about NSAID
indications/contraindications to be able to refer on to the
GP for prescription when required.
For more chronic conditions involving swelling I consider
topical NSAIDs helpful if the dosage is right. I would
appreciate more information regarding the legal side,
contraindications, and any research regarding topical
NSAIDs effect on tissue healing rates.
While massaging or using ultrasound, I like the “double”
advantage of using NSAID gel medium to help the cause
of my patients. Accountability of oral NSAIDs should
remain with trained pharmacists/doctors.
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Figure 1 Percentage of males and females working in health sectors.
Table 3 Key themes synthesized from the interviews
Common questions asked of physiotherapists 
Commonly encountered NSAIDs oral medications and topical gels 
Concerns regarding usage of NSAIDs 
Knowledge 
Opportunities for education
Opinions of physiotherapists regarding NSAIDs 
Involvement of GPs and pharmaceutical companies with
physiotherapists
Practices that were contrary to the legislation or challenged the nature
of the interpretation of the legislation Therapeutics and Clinical Risk Management 2005:1(1) 73
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Concerns regarding usage of NSAIDs
Almost all interviewed physiotherapists reported having
concerns about the way NSAIDs were, or could be used in
their practice. Commonly reported concerns were lack of
proper knowledge about NSAIDs when dealing with
patients, lack of adequate education of patients by the
relevant prescriber or supplier (GPs and pharmacists), use
of “cocktails” of drugs, long-term use of NSAIDs, etc.
NSAIDs kill people. Drugs and side effects cause so many
problems because of inadequate education. Short-term
NSAIDs for some patients seem to be useful. Long-term
NSAIDs need to be prescribed and monitored by doctors.
Over-the-counter drugs should only be advised by physios
who have not been trained.
Knowledge
Almost all the physiotherapists interviewed reported that
their knowledge of NSAIDs was poor to average, and few
reported that their undergraduate or postgraduate education
had been sufficient for them to understand the finer aspects
of NSAIDs action or range of effects.
I will normally suggest (patients) see their GP. If their
general health is good, I may recommend an over-the-
counter NSAID, ie, gel or tablet, but to discuss it with the
pharmacist first. I only warn them of the GI
[gastrointestinal] problems as that is all I am aware of. It
would be good to know more, but I don’t think that it is
our role to prescribe the higher dose NSAIDs as we have
poor knowledge on drugs and interactions with other
medications.
Opportunities for education
Matching physiotherapist concerns about their knowledge
on NSAIDs was the lack of available and easily accessible
education provided to practicing physiotherapists about the
use of NSAIDs. This involved not only Quality Use of
Medicines (QUM)1 principles and legislation details, but
also information on existing and new NSAIDs, their actions,
contraindications, dosages, and side effects. Often
physiotherapists reflected on how little education they had
received since graduation. Some suggested that there be
increased exposure during undergraduate and postgraduate
training, followed by regular and clinically focused updates
from their respective professional organizations, relevant
to their areas of practice. Knowledge of currently available
medications, their action, and possible side effects is an area
requiring increased focus.
As physiotherapists, we are often the first point of contact
for patients with musculoskeletal disorders. It is our
responsibility to recognize conditions which may respond
more favourably to NSAIDs and recommend or refer
appropriately. It is not our responsibility to recommend
particular medications, even if we had more up-to-date
information on drug actions and interactions.
Opinions of physiotherapists regarding
NSAIDs
Three distinct sets of opinions were identified concerning
the use of NSAIDs in physiotherapy clinical practice. The
first opinion, mostly expressed by hospital-based
physiotherapists, was that physiotherapists should have
nothing to do with any medications.
I think that we should stick to our core practice and I don’t
think that includes prescribing medications. Although I
think that we should be able to access NSAIDs for patients
by referring to pharmacists.
The second opinion was that since a large number of
NSAIDs were available over-the-counter, physiotherapists
should be able to recommend and prescribe them. The
overwhelming feeling from physiotherapists who gave this
response was that physiotherapists should be able to
recommend/suggest NSAIDs for specific conditions, but it
should be left up to the prescribing doctor/pharmacist to
undertake all the screening issues, dosage, etc.
I think NSAIDs complement physiotherapy treatment and
are very useful where an acute inflammatory condition
exists. As certain drugs which are NSAIDs are already
available over the counter (and are marketed as pain killers
rather than NSAIDs – and are often sold without adequate
warnings or advice on the packet), I think it is appropriate
for physiotherapists to advise on their use and offer
adequate advice (which is not always forthcoming from
pharmacy assistants).
The third opinion came mostly from rural physiotherapists
and physiotherapists who worked on the sidelines at sports
and recreational activities, who reported that they were often
the first contact practitioner with limited opportunity to
consult a health professional. These physiotherapists
believed that they should be in a position to “prescribe”
NSAIDs but still felt it was up to pharmacists to deal with
issues of dosage, etc.
I think they [NSAIDs] have a huge place in physio practice.
In patients with acute injuries, I am frequently referringTherapeutics and Clinical Risk Management 2005:1(1) 74
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them back to the GP to get a prescription for NSAIDs. I
think physios should be able to prescribe them themselves
(saving their patients and doctors visits and money), but
only once they have sufficient knowledge to prescribe safe
dosages, contraindications, etc.
Involvement of GPs and pharmaceutical
companies with physiotherapists
Most physiotherapists interviewed reported that they often
consulted GPs regarding NSAID use. Interestingly, not one
physiotherapist had been consulted by pharmaceutical
companies about their products, even though
physiotherapists perceived themselves as regular customers.
Many of the above quotes represent these views.
Practices that were contrary to the
legislation, or which challenged the
nature of the interpretation of the
legislation
• The use of topical NSAIDs as an adjunct to
electrophysical modalities, particularly when used as a
“first-aid” for acute musculoskeletal pain (as a contact
medium for ultrasound).
• The use of topical NSAIDs as a massage interface.
• The recommendation to use specific oral NSAIDs as an
adjunct to physiotherapy management, particularly when
medical or pharmaceutical advice is not available (for
instance in rural areas, or over weekends).
• The difference between giving advice as an informed
therapist (with up-to-date knowledge of pharmacology),
compared with giving advice as a concerned citizen
(where evidence is anecdotal at best).
NSAIDs use is a daily issue in my practice. As first contact
practitioner, it would make a lot of sense to incorporate
this functionality into the physiotherapists’ arsenal. It
would save on unnecessary duplication of visits to a GP.
As experts in musculoskeletal pain/movement and also
feel, I am in a very good position to differentiate
mechanical from chemical – inflammatory conditions.
The interviews provided information that described common
scenarios illustrating the challenges faced by
physiotherapists using NSAIDs. The following section
reports on three such cases (using fictitious names), which
highlight issues that were raised during the interviews,
and which reflect the “gray areas” in the interpretation of
current legislation.
Case studies
1. Bill, a physiotherapist with 5-years experience, provides
physiotherapy services on a voluntary basis to the local
netball team every Saturday. He believes that this
exposure will improve his business on Monday
mornings. Most of the conditions he encounters on
Saturdays are acute inflammatory musculoskeletal
conditions. He regularly uses topical NSAIDs in
conjunction with electrophysical agents. He was
horrified to receive a letter from the local registration
board regarding a complaint filed against him by a
netballer he had treated with NSAIDs. Subsequent to
his treatment, she had developed a skin rash that was
resistant to medical intervention. The treating doctor had
diagnosed the rash as related to topical NSAID
administration and had suggested the netballer take
this course of action because he considered the
physiotherapist’s intervention to be professionally
inappropriate.
2. Sandra works as a rural physiotherapist in private
practice. Her clientele are generally elderly folk with
chronic conditions. She often treats musculoskeletal
complaints of many years standing and is concerned at
how much the pain and dysfunction from these
conditions restrict her patients’ activities of daily living.
Sandra had limited access to up-to-date pharmacology
advice because the general practitioner was elderly and
by his own admission was out of touch with current
practice. The local chemist only operated two days a
week in town. One Friday evening, she was consulted
by Mr Smith, an 80-year-old with acute-on-chronic low
back pain. He hadn’t slept for several nights and was
barely able to stand upright. Sandra could see he required
multifactorial management. She provided him with
appropriate physiotherapy intervention to reduce his pain
and improve his range of movement. She also gave him
a sheet of NSAIDs from her own personal supply
because there would not be a chemist service until
Tuesday. On Saturday evening, Mr Smith was admitted
to the local hospital in severe discomfort and with
shortness of breath. On investigation it appeared to be
related to an adverse interaction between the oral
NSAIDs and his antihypertensive and cardiac
medications. Sandra was very lucky that neither
Mr Smith nor the admitting doctor took the matter
any further.
3. Jill reminded her family that she would be a little late
coming home this evening. Tonight was the regularTherapeutics and Clinical Risk Management 2005:1(1) 75
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bimonthly visit by the local pharmacist to her
physiotherapy practice. All 6 of her staff would be
attending, and there were a number of physiotherapists
from other practices who were invited. Tonight the
pharmacist was presenting information on recently
released, over-the-counter NSAIDs. If tonight’s
presentation was as entertaining and informative as the
previous presentation by this pharmacist (on asthma
medications), it would be a very worthwhile extra hour
spent at work. In her undergraduate and postgraduate
training, Jill had been exposed to less than 10 hours of
information on pharmacology, much of which had been
forgotten in the following years. She had a Monthly Index
of Medical Specialties on her shelf but this was several
years old, and trying to find the information was very
time consuming. The arrangement with the local
pharmacist had been in place a year after Jill had queried
the nature of a prescription drug taken by one of her
patients. It was quickly apparent that physiotherapists
could learn a great deal about practical pharmacology
from the pharmacists, and it was also apparent that the
pharmacist could learn a lot about musculoskeletal
symptom management from the therapists. Entertaining
as these sessions were, there was the additional benefit
of the continuing education points which Jill had
negotiated for her staff with the local physiotherapy
association for attending.
Discussion
This research identified many core issues associated with
NSAIDs and their use by physiotherapists. While it is
increasingly more common for physiotherapists to be
routinely using and recommending NSAIDs as adjunct to
traditional therapy modalities, there is limited undergraduate
and postgraduate training in the field of pharmacology,
quality use of medicines, ethics of prescription, and key
legislative aspects of NSAID use. Physiotherapists who
work as primary contact practitioners assume the
responsibility for an accurate diagnosis and key decisions
on interventions for the acute and chronic management of
musculoskeletal conditions. Managing inflammation is one
of the key roles in this process. Physiotherapy training
allows for the appropriate use of electophysical agents,
exercises, and manual therapy but not for directly
prescribed medicines.
Prescribing NSAIDs is currently the domain of medical
practitioners, and supply of the same is the domain of the
pharmacist who has the knowledge and legislative
responsibility to provide advice to patients regarding
appropriate use and contraindications. The gray area for
physiotherapists, highlighted in this research is in the
definition of their responsibility to patients when providing
“advice” on NSAIDs. While the legislation is clear and
specifies that physiotherapists cannot prescribe, provide, or
sell NSAIDs, it is unclear regarding the nature and impact
of recommendation by physiotherapists relevant to their
personal or professional experience. In addition, while the
legislation supports physiotherapists in recommending that
patients seek advice from their medical practitioner and/or
pharmacist, and supports the use of topical NSAIDs as an
adjunct to electrophysical therapy and manual therapy, it is
unclear regarding the need for the therapist to obtain explicit
consent from the patient to use NSAIDs or obtain
information from the patient regarding past effects of using
NSAIDs.
Recommending the use of a therapeutic product in this
instance requires clarification, particularly as a medication
misadventure related to current physiotherapy advice could
well put a physiotherapist in a difficult legal situation. If
physiotherapists recommend (directly to patients) the use
of a particular NSAID, they are operating on the same
anecdotal evidence level as any lay person, because of the
lack of specific training in pharmacology. Furthermore,
while the legislation currently supports the sale of “S2
Expect” NSAIDs over-the-counter and in supermarket
shelves, the explicit recommendation by a health
professional, in this instance a physiotherapist, could be
assumed by the patient to be based on greater knowledge
than their own, as it is provided by a health professional.
This assumes that the physiotherapist is adequately trained
and informed about drug indications, contraindications,
dosage, and usage. The interviews did not reflect this. Similar
dilemmas exist when using NSAIDs as topical agents
(massage) and in the form of phonopheresis (ultrasound).
This is often undertaken without explicit consent from the
patients and, currently, evidence in the literature is lacking
to support the use of NSAIDs in this adjunct form.
Physiotherapists, however, can recommend the generic use
of antiinflammatory and direct patients to the appropriate
evidence-based sources.
Conclusion
The legislation relating to NSAID use by physiotherapists
is clear. Our interviews highlighted the potential for
medication misadventure for patients using other
medications, or who were hypersensitive to NSAIDs,Therapeutics and Clinical Risk Management 2005:1(1) 76
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because of physiotherapists’ variable knowledge of the
legislation, and the variable ways in which physiotherapists
interpreted the legislation and acted it out. This study also
identified opportunities for physiotherapists to unknowingly
place themselves at risk of unprofessional behavior by
providing advice to patients which may be misinterpreted
or result in actual harm.
The areas that could challenge physiotherapists’
understanding of the legislation include:
• The use of topical NSAIDs as an adjunct to
electrophysical modalities, particularly when used in a
“first-aid” scenario for acute musculoskeletal conditions.
• The use of topical NSAIDs as a massage interface.
• The recommendation to use specific oral NSAIDs as an
adjunct to physiotherapy management, particularly when
medical or pharmaceutical advice is not available (for
instance in rural areas, or over weekends).
• The difference between giving advice as an informed
therapist (which presumes up-to-date knowledge of
pharmacology), compared with giving advice as a
concerned citizen (where evidence is anecdotal at best).
While the inclusion of NSAIDs in management plans by
physiotherapists has the potential to improve patient
outcomes, this approach should be undertaken with advice
from pharmacists or medical practitioners. Physiotherapists
should be aware of the pitfalls of not seeking this advice for
every patient.
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and Ageing 2002).
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